← All trials
NCT06170463
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2022
- Primary completion
- Mar 1, 2023
- Completion date
- Apr 15, 2023
- First posted
- Dec 14, 2023
- Last posted
- Dec 20, 2023
- Enrollment
- 210
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zagazig UniversityLead sponsor
- Zagazig UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.